<DOC>
	<DOCNO>NCT00946101</DOCNO>
	<brief_summary>The purpose study determine safety descriptive immunogenicity H1N1 influenza vaccine healthy child .</brief_summary>
	<brief_title>A Study Evaluate Safety HIN1 Monovalent Vaccine ( MEDI3414 ) Children 2 17 Years Age</brief_title>
	<detailed_description>The primary objective study assess safety descriptive immunogenicity monovalent influenza virus vaccine contain new 6:2 influenza virus reassortant healthy child .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female , 2 17 year age ( yet reach 18th birthday ) time randomization Healthy medical history physical exam Written inform consent locally require authorization ( eg , Health Insurance Portability Accountability Act [ HIPAA ] United States America [ USA ] , European Union [ EU ] Data Privacy Directive EU write informed assent ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation Females childbearing potential , ( ie , unless premenarchal , surgically sterile [ eg , bilateral tubal ligation , bilateral oophorectomy , hysterectomy ] , sterile male partner , practice abstinence ) must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , use condom spermicide sexual partner ) 30 day prior first dose investigational product , must agree continue use precaution 60 day second dose investigational product . In addition , subject must also negative urine blood pregnancy test screening , screen Day 1 occur day , day vaccination prior randomization . Investigator judgment require assess childbearing potential preadolescent adolescent girl . Males , unless sexually active , must use effective method birth control female partner must agree continue use contraceptive precaution least 30 day second dose investigational product ( Day 1 Day 59 study ) Subject 's legal representative available telephone Subject/subject 's legal representative able understand comply requirement protocol , judge investigator Ability complete followup period 180 day Dose 2 require protocol History hypersensitivity component investigational product include egg egg protein , gelatin arginine , serious , lifethreatening , severe reaction previous influenza vaccination History hypersensitivity gentamicin Any condition inactivate influenza vaccine indicate , include chronic disorder pulmonary cardiovascular system ( eg , asthma ) , chronic metabolic disease ( eg , diabetes mellitus ) , renal dysfunction , hemoglobinopathy require regular medical followup hospitalization precede year Acute febrile ( &gt; 100.0°F oral equivalent ) and/or clinically significant respiratory illness ( eg , cough sore throat ) within 14 day prior randomization History asthma , child &lt; 5 year age , history recurrent wheeze Any known immunosuppressive condition immune deficiency disease , include human immunodeficiency virus infection , ongoing immunosuppressive therapy History GuillainBarré syndrome A household contact severely immunocompromised ( eg , hematopoietic stem cell transplant recipient , period immunocompromised individual require care protective environment ) ; subject additionally avoid close contact severely immunocompromised individual least 21 day receipt investigational product Receipt investigational agent within 30 day prior randomization , expect receipt 30 day second dose investigational product ( use license agent indication list package insert permit ) Use aspirin salicylatecontaining product within 30 day prior randomization expect receipt 30 day final vaccination Expected receipt antipyretic analgesic medication ( nonsalicylatecontaining ) daily every day basis randomization 14 day receipt dose investigational product Administration intranasal medication within 14 day prior randomization , expect receipt 14 day administration dose investigational product Receipt nonstudy vaccine within 30 day Dose 1 expect receipt nonstudy vaccine within 30 day Dose 2 Known suspect mitochondrial encephalomyopathy Adolescent subject pregnant nursing mother Any condition ( eg , chronic cough , allergic rhinitis ) , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result Subject , legal representative , immediate family member subject employee clinical study site otherwise involved conduct study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>randomize , double-blind , placebo-controlled</keyword>
</DOC>